A late-stage, well-funded “safe oral” ulcerative colitis contender with takeover-like upside—yet still one maintenance-trial readout away from binary outcomes.
Overview
Abivax (Euronext/Nasdaq: ABVX) is presented as a high-upside, high-stakes late-stage biotech story in Immunology & Inflammation, anchored by its lead asset Obefazimod (ABX464) for ulcerative colitis. The company’s thesis has evolved from speculative development to a more “derisked” pre-commercial profile after positive top-line Phase 3 induction results (ABTECT-1 and ABTECT-2) reported in July 2025, showing statistically significant Week‑8 clinical remission in moderate-to-severe UC, including difficult refractory patients, with a differentiated safety narrative versus competing oral classes. Abivax targets a “Goldilocks” market gap: a once-daily oral therapy with meaningful efficacy but without JAK black-box warnings or S1P monitoring complexity. Financially, it executed a major post-data capital raise (~$700M net), ending Sept 30, 2025 with ~€590M cash and runway into Q4 2027—covering the key maintenance readout (Q2 2026) and expected US/EU filings (H2 2026). CEO Marc de Garidel’s M&A-driven track record and strong institutional backing reinforce alignment toward value realization, though the maintenance trial remains the primary binary risk.